<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>SURAKSHA</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">SURAKSHA</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="suraksha-diagnostic-limited" class="section level1">
<h1>Suraksha Diagnostic Limited</h1>
<p><a href="/reports01/index/industry/rp-HealthcareServiceProvider.html">Healthcare Service Provider</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SURAKSHA.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SURAKSHA.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SURAKSHA.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SURAKSHA.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SURAKSHA.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SURAKSHA.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SURAKSHA.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SURAKSHA.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SURAKSHA.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-08 </em></p>
<p>Based on a comprehensive analysis of the provided earnings release, investor presentation, and corporate disclosures for <strong>Suraksha Diagnostic Limited</strong> (as of 30 September 2025), we present a structured assessment of the company‚Äôs <strong>headwinds, tailwinds, growth prospects, and key risks</strong>. The insights are derived from financial performance, operating metrics, strategic direction, market positioning, and industry dynamics.</p>
<hr />
<div id="company-overview-contextual-foundation" class="section level6">
<h6>üîç <strong>Company Overview (Contextual Foundation)</strong></h6>
<ul>
<li><strong>Market Position</strong>: Largest integrated diagnostic chain in Eastern India.</li>
<li><strong>Presence</strong>: West Bengal, Bihar, Assam, Meghalaya.</li>
<li><strong>Services</strong>: Pathology, Radiology, Doctor Consultations (Polyclinic), Home Collection, Pharmacy.</li>
<li><strong>Core Strategy</strong>: Hub-and-spoke model; expansion via organic growth and selective M&amp;A; technology-driven patient experience.</li>
<li><strong>Listed Since</strong>: 2020 (BSE: 544293, NSE: SURAKSHA).</li>
<li><strong>Recent Milestones</strong>:
<ul>
<li>Launch of <strong>Suraksha Genomics</strong> (Q1 FY26).</li>
<li>Strategic investment in <strong>Fetomat Wellness</strong>, a leading maternal-fetal care chain.</li>
<li>63 diagnostic centers as of H1 FY26 (including 2 Fetomat centers).</li>
</ul></li>
</ul>
<hr />
</div>
<div id="tailwinds-factors-driving-growth" class="section level6">
<h6>üå¨Ô∏è <strong>Tailwinds: Factors Driving Growth</strong></h6>
<div id="strong-market-opportunity-in-an-underserved-region" class="section level9">
<p class="heading">1. <strong>Strong Market Opportunity in an Underserved Region</strong></p>
<ul>
<li>Eastern India (especially West Bengal) is <strong>low-penetration and highly fragmented</strong>, with minimal presence of organized diagnostic chains.</li>
<li>Only <strong>1.62 NABL labs per million population</strong> (vs.¬†North: 1.6, South: 1.6, West: 0.96), showing <strong>acute undersupply</strong>.</li>
<li>West Bengal alone contributes <strong>95.5% of FY25 revenue</strong>, but this reflects high penetration potential, not over-saturation.</li>
<li>Market CAGR forecasted at <strong>10.5‚Äì12.5% (FY24‚ÄìFY28)</strong> ‚Äì above the national average.</li>
</ul>
<blockquote>
<p>‚ö° Tailwind: First-mover advantage in a growing, underpenetrated market.</p>
</blockquote>
<hr />
</div>
<div id="solid-organic-growth-and-volume-led-expansion" class="section level9">
<p class="heading">2. <strong>Solid Organic Growth and Volume-Led Expansion</strong></p>
<ul>
<li><strong>Q2 FY26 Total Income</strong>: ‚Çπ795.8 million (+16.9% YoY).</li>
<li><strong>H1 FY26 Total Income</strong>: ‚Çπ1,530.72 million (+17.8% YoY).</li>
<li>Volume growth driven by:
<ul>
<li><strong>+17.5% YoY growth in patients</strong> (0.61M ‚Üí 0.71M).</li>
<li><strong>+25.6% YoY growth in tests</strong> (3.29M ‚Üí 4.13M).</li>
<li>Improvement in <strong>tests per patient</strong> (5.41 ‚Üí 5.78), indicating cross-selling success.</li>
</ul></li>
</ul>
<blockquote>
<p>‚ö° Tailwind: Scalable hub-and-spoke model is gaining traction and feeding volume growth.</p>
</blockquote>
<hr />
</div>
<div id="strategic-diversification-and-vertical-integration" class="section level9">
<p class="heading">3. <strong>Strategic Diversification and Vertical Integration</strong></p>
<ul>
<li><strong>Launch of Suraksha Genomics (July 2025)</strong>: Entry into high-growth molecular diagnostics (NIPT, exome sequencing, pharmacogenomics).
<ul>
<li>Genomics is a future growth lever with high margins and low competition in regional markets.</li>
</ul></li>
<li><strong>Acquisition of 63% in Fetomat</strong> (Apr 2025): Adds 2 centers and positions Suraksha in women‚Äôs health and prenatal diagnostics.
<ul>
<li>Synergy with genomics enhances early detection, long-term wellness narrative.</li>
<li>Cross-referral opportunities with polyclinics.</li>
</ul></li>
</ul>
<blockquote>
<p>‚ö° Tailwind: New revenue streams (genomics, specialist care) diversify risk and boost long-term margin potential.</p>
</blockquote>
<hr />
</div>
<div id="proven-operational-model-and-high-brand-recall" class="section level9">
<p class="heading">4. <strong>Proven Operational Model and High Brand Recall</strong></p>
<ul>
<li><strong>Hub-and-Spoke Network</strong>: Central labs, 7 satellite labs, 63 diagnostic centers, 173 collection centers.</li>
<li><strong>Polyclinic Model</strong>: 160+ chambers, 1,000+ doctors ‚Äì drives patient footfall and ancillary revenue.</li>
<li><strong>Awards &amp; Recognition</strong>: Consistent brand accolades (e.g., ‚ÄúOutstanding Diagnostic Chain of Eastern India‚Äù 2022, 2025).</li>
<li>Strong <strong>operational discipline</strong>: Mature centers deliver <strong>37‚Äì38% EBITDA margins</strong>.</li>
</ul>
<blockquote>
<p>‚ö° Tailwind: High barriers to imitation; brand trust drives retention and pricing power.</p>
</blockquote>
<hr />
</div>
<div id="digital-and-operational-efficiency" class="section level9">
<p class="heading">5. <strong>Digital and Operational Efficiency</strong></p>
<ul>
<li><strong>LIMS, RIS, PACS, ERP Integrations</strong>: Streamlining turnaround time, reducing errors.</li>
<li><strong>Online booking, home collection, SMS alerts</strong>: Improving customer convenience.</li>
<li>Automation and AI investments (highlighted in Genomics section) pave way for scalability.</li>
</ul>
<blockquote>
<p>‚ö° Tailwind: Technology enhances unit economics and customer acquisition cost efficiency.</p>
</blockquote>
<hr />
</div>
</div>
<div id="headwinds-short-term-challenges" class="section level6">
<h6>üå™Ô∏è <strong>Headwinds: Short-Term Challenges</strong></h6>
<div id="margin-pressure-from-rapid-expansion" class="section level9">
<p class="heading">1. <strong>Margin Pressure from Rapid Expansion</strong></p>
<ul>
<li><strong>Q2 FY26 EBITDA Margin: 31.7%</strong> (down from 36.7% YoY).</li>
<li>Reason: <strong>21 newly opened centers</strong>, of which 15 are less than 1 year old.</li>
<li><strong>EBITDA margin for &lt;1-year-old centers</strong>: -50.3% (Q2 FY26).</li>
<li><strong>New centers dilute overall profitability</strong> until they stabilize (~18‚Äì24 months).</li>
</ul>
<blockquote>
<p>üîÑ Headwind: Aggressive expansion is negatively impacting near-term margins; investors may pressure for profitability.</p>
</blockquote>
<hr />
</div>
<div id="decline-in-revenue-profitability-qoq-and-yoy" class="section level9">
<p class="heading">2. <strong>Decline in Revenue &amp; Profitability (QoQ and YoY)</strong></p>
<ul>
<li><strong>PAT down -13.1% YoY</strong> in Q2 (‚Çπ88.28M vs ‚Çπ101.56M).</li>
<li><strong>PAT Margin: 11.2%</strong> (down from 15.2%), despite higher revenue.</li>
<li><strong>QoQ revenue growth</strong>: 8.3%, but <strong>PAT down 3.8%</strong>, indicating cost inflation and startup drag.</li>
</ul>
<blockquote>
<p>üîÑ Headwind: Revenue growth not translating into proportional profit growth; margin expansion delayed.</p>
</blockquote>
<hr />
</div>
<div id="asset-inflation-and-working-capital-strain" class="section level9">
<p class="heading">3. <strong>Asset Inflation and Working Capital Strain</strong></p>
<ul>
<li><strong>Total Assets increased to ‚Çπ3,802M</strong> in H1 FY26 vs ‚Çπ3,335M in FY25.</li>
<li>Fixed asset growth (PPE: ‚Çπ1,471M ‚Üí ‚Çπ1,670M) and capex-heavy expansion.</li>
<li><strong>Cash flow from operations: ‚Çπ454.1M</strong>, but capex: <strong>‚Çπ234.6M</strong>.</li>
<li><strong>Cash and equivalents: ‚Çπ21.07M</strong> (a low buffer), down from ‚Çπ22.47M.</li>
<li>Net cash: <strong>declined by ‚Çπ1.4M</strong> (vs ‚Çπ3.58M increase in FY25).</li>
</ul>
<blockquote>
<p>üîÑ Headwind: Capital-intensive model with thinning cash reserves; future funding may be needed unless operating cash improves.</p>
</blockquote>
<hr />
</div>
<div id="revenue-per-test-declining" class="section level9">
<p class="heading">4. <strong>Revenue per Test Declining</strong></p>
<ul>
<li><strong>Avg. Revenue per Test: ‚Çπ367</strong> in H1 FY26 vs ‚Çπ388 in H1 FY25.</li>
<li>Due to:
<ul>
<li>Mix effect (higher share of lower-priced pathology tests).</li>
<li>Pricing pressure in regional markets.</li>
<li>Volume growth from cost-sensitive segments.</li>
</ul></li>
</ul>
<blockquote>
<p>üîÑ Headwind: Could constrain long-term margin recovery unless offset by higher-value tests (e.g., genomics).</p>
</blockquote>
<hr />
</div>
</div>
<div id="growth-prospects" class="section level6">
<h6>üìà <strong>Growth Prospects</strong></h6>
<table>
<colgroup>
<col width="61%" />
<col width="18%" />
<col width="20%" />
</colgroup>
<thead>
<tr class="header">
<th>Lever</th>
<th>Outlook</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Geographic Expansion</strong></td>
<td>High</td>
<td>9 new centers launched in H1; 9 planned in H2. Strong growth room in Bihar, Assam, Meghalaya. PPP model (e.g., S.D. Hospital) enables faster traction.</td>
</tr>
<tr class="even">
<td><strong>Hub-and-Spoke Scalability</strong></td>
<td>High</td>
<td>Proven success in Kolkata. Replicable in tier-2/3 cities for cost-efficient access and volume capture.</td>
</tr>
<tr class="odd">
<td><strong>Polyclinic Integration</strong></td>
<td>High</td>
<td>Doctor footfall drives test volume. Revenue from consultancy (+pharmacy) diversifies income.</td>
</tr>
<tr class="even">
<td><strong>Genomics &amp; Specialty Testing</strong></td>
<td>Very High</td>
<td>High-margin, low-competition space. NIPT, cancer screening, rare disease diagnosis align with national healthcare priorities.</td>
</tr>
<tr class="odd">
<td><strong>Inorganic Growth (M&amp;A)</strong></td>
<td>Medium</td>
<td>Fetomat acquisition sets precedent. Open to more deals in Eastern/Northeast India. Due diligence on brand, tech, customer base.</td>
</tr>
<tr class="even">
<td><strong>B2B and Institutional Sales</strong></td>
<td>Medium</td>
<td>Untapped corridor. Corporate tie-ups, health camps, insurance partnerships can boost volume.</td>
</tr>
<tr class="odd">
<td><strong>Technology and AI</strong></td>
<td>Medium‚ÄìHigh</td>
<td>Automation improves efficiency. Genomics/AI potential to create IP and research collaborations.</td>
</tr>
</tbody>
</table>
<blockquote>
<p>‚ñ∂ <strong>Outlook</strong>: Strong <strong>medium to long-term growth runway</strong>, driven by <strong>scaling, service expansion, and market leadership</strong>.</p>
</blockquote>
<hr />
</div>
<div id="key-risks" class="section level6">
<h6>‚ö†Ô∏è <strong>Key Risks</strong></h6>
<table>
<colgroup>
<col width="41%" />
<col width="35%" />
<col width="23%" />
</colgroup>
<thead>
<tr class="header">
<th>Risk Category</th>
<th>Description</th>
<th>Impact</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Operational Risk</strong></td>
<td>High proportion of new centers unprofitable; long gestation period may strain balance sheet.</td>
<td>High ‚Äì delays margin normalization; cash burn possible.</td>
</tr>
<tr class="even">
<td><strong>Market Risk</strong></td>
<td>Local competitors or price wars in pricing-sensitive markets (e.g., West Bengal).</td>
<td>Medium ‚Äì high pricing power but volume-driven strategy may face undercutting.</td>
</tr>
<tr class="odd">
<td><strong>Execution Risk</strong></td>
<td>Continued aggressive capex and hiring; integration of acquired entities (Fetomat).</td>
<td>Medium ‚Äì risk of over-leveraging or cultural misalignment.</td>
</tr>
<tr class="even">
<td><strong>Regulatory Risk</strong></td>
<td>Diagnostic pricing norms under Ayushman Bharat or state schemes may impact profitability.</td>
<td>Medium ‚Äì especially if public partnerships grow.</td>
</tr>
<tr class="odd">
<td><strong>External Risk</strong></td>
<td>Economic slowdown, reduced household healthcare spending, or diagnostic test deferrals.</td>
<td>Medium ‚Äì diagnostics are semi-discretionary for many.</td>
</tr>
<tr class="even">
<td><strong>Technology Risk</strong></td>
<td>Rapid advancements may make current equipment/software obsolete; cybersecurity threats.</td>
<td>Low‚ÄìMedium ‚Äì mitigated by ongoing IT investments.</td>
</tr>
<tr class="odd">
<td><strong>Succession Risk</strong></td>
<td>Heavy reliance on promoters (Dr.¬†Somnath Chatterjee, Ritu Mittal). Board experienced, but concentration exists.</td>
<td>Medium ‚Äì though professional CFO and CS suggest maturity.</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="summary-investment-thesis-positioning" class="section level6">
<h6>‚úÖ <strong>Summary: Investment Thesis &amp; Positioning</strong></h6>
<table>
<colgroup>
<col width="40%" />
<col width="60%" />
</colgroup>
<thead>
<tr class="header">
<th>Category</th>
<th>Assessment</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Growth Trajectory</strong></td>
<td>Positive: Strong top-line momentum (17.8% YoY revenue growth), supported by volume and new centers. Expansion pipeline robust.</td>
</tr>
<tr class="even">
<td><strong>Profitability</strong></td>
<td>Near-term pressure: Margin dilution due to new centers. Long-term recovery expected as centers mature.</td>
</tr>
<tr class="odd">
<td><strong>Competitive Position</strong></td>
<td>Strong: Market leader in Eastern India; differentiated via polyclinics, tech, brand. Low competition in core geography.</td>
</tr>
<tr class="even">
<td><strong>Innovation</strong></td>
<td>Accelerating: Genomics and AI investments position company at forefront of precision diagnostics.</td>
</tr>
<tr class="odd">
<td><strong>Valuation Potential</strong></td>
<td>Under-penetrated market + expansion story supports premium valuation if execution continues.</td>
</tr>
<tr class="even">
<td><strong>Investor Consideration</strong></td>
<td>Suitable for <strong>growth-oriented investors with medium-term horizon</strong>. Not yet a ‚Äúcash cow‚Äù but building into a dominant regional player.</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="conclusion" class="section level6">
<h6>üîö <strong>Conclusion</strong></h6>
<p><strong>Suraksha Diagnostic Limited</strong> is in a pivotal phase of <strong>scaling-to-profitability transition</strong>:</p>
<ul>
<li><strong>Tailwinds</strong>: Large untapped market in Eastern India, scalable hub-and-spoke model, rising demand for diagnostics, new high-margin verticals (genomics), proven brand and operations.</li>
<li><strong>Headwinds</strong>: Margin pressure from new centers, declining revenue/test, cash flow constraints.</li>
<li><strong>Growth Levers</strong>: Organic expansion, M&amp;A, B2B, polyclinic integration, technology.</li>
<li><strong>Key Risks</strong>: Execution, gestation period of new centers, competition, and capital needs.</li>
</ul>
<p>üéØ <strong>Final Verdict</strong>: <strong>Constructive long-term outlook</strong>. The company is investing aggressively today to <strong>dominate a high-growth regional market</strong>. If it manages capex discipline, integrates acquisitions well, and leverages its <strong>integrated diagnostics + doctor network model</strong>, it is well-positioned to <strong>emerge as a dominant player in Indian diagnostics with superior unit economics in 3‚Äì5 years</strong>.</p>
<hr />
<p><strong>Monitoring Indicators for Investors</strong>: - Margin recovery (watch EBITDA margin trend). - Cash flow and working capital stability. - Progress on Genomics revenue contribution. - Q3 FY26 center maturity and profitability. - Execution of H2 FY26 expansion plan (9 centers).</p>
<blockquote>
<p><em>‚ÄúToday‚Äôs pains are tomorrow‚Äôs profits‚Äù ‚Äì Suraksha is betting on it.</em></p>
</blockquote>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
